45 results
8-K
EX-99.2
AXLA
Axcella Health Inc.
6 May 20
Axcella Announces Positive Top-Line Data from AXA1125-003 Clinical Study Showing Multifactorial Activity in Adult Subjects with NAFLD
8:09am
- 4, fibrosis 4; HOMA - IR, homeostasis model assessment of insulin resistance ; MRI - PDFF, magnetic resonance imaging proton density fat fraction … -15 0 Relative change, mean (SE), % ALT, alanine aminotransferase; cT1, corrected T1; FIB - 4, fibrosis 4; HOMA - IR, homeostasis model assessment
CORRESP
AXLA
Axcella Health Inc.
24 Apr 19
Correspondence with SEC
12:00am
recent third-party valuations of its common stock and the Board’s assessment of additional objective and subjective factors that it believed were relevant … the future-event scenarios based on the Company’s assessment of its development pipeline and market conditions at that time. The future equity values
8-K
EX-99.1
AXLA
Axcella Health Inc.
23 Mar 20
Axcella Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
4:03pm
, post-baseline assessment with continued improvement through 16 weeks. These findings were highlighted at the 2020 NASH-TAG Conference in January
424B4
szl8w4tvu85dl4oz8pp
14 May 20
Prospectus supplement with pricing info
5:15pm
10-K
pbg a80nwem5397
23 Mar 20
Annual report
4:12pm
8-K
EX-99.1
pk6oc3sq7zg 10
5 Aug 20
Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results
8:22am
S-1
xv0fge rgl
12 Apr 19
IPO registration
7:02am
424B4
dmq 8ucfg
9 May 19
Prospectus supplement with pricing info
4:29pm
DRS/A
yjq16hm9ti
15 Mar 19
Draft registration statement (amended)
12:00am
DRS
t56lmnvd28 e25vikmg
3 Apr 20
Draft registration statement
12:00am
DRS
vka4e yh6buva
28 Jan 19
Draft registration statement
12:00am